磷酸奥司他韦的活性代谢产物(奥司他韦羧酸盐)是选择性的流感病毒神经氨酸酶抑制剂，能够抑制甲型 和乙型流感病毒的神经氨酸酶活性，通过抑制病毒从被感染的细胞中释放，减少甲型或乙型流感病毒的 播散。磷酸奥司他韦干混悬剂用于2周龄及以上年龄患者的甲型和乙型流感治疗和1岁及以上年龄人群的 甲型和乙型流感预防。 智通财经APP讯，普洛药业(000739.SZ)发布公告，近日，公司控股子公司浙江普洛康裕制药有限公司收 到国家药品监督管理局签发的磷酸奥司他韦干混悬剂《药品注册证书》。 ...

Group 1 - Pro Pharmaceutical has obtained a food production license for bat moth mycelium powder, categorized as a health food [1] - Zhongqi Co., Ltd. has had its application for issuing convertible bonds accepted by the Shenzhen Stock Exchange [2] - Baijun Medical's subsidiary has received approval for its collagen implant product, the first of its kind for facial dermal injections in China [3] Group 2 - Sinopharm Modern's subsidiary has received a drug registration certificate for Bumetanide injection, used for edema, hypertension, and preventing acute kidney failure [4] - Landun Optoelectronics has terminated the purchase of a stake in Star Si Semiconductor, with no payment made for the equity transfer [5] - Zhaoxin Co., Ltd. plans to acquire 70% of Youde New Energy for a maximum price of 220 million yuan, positioning it as a controlling subsidiary [6] Group 3 - Chongqing Rural Commercial Bank has had the qualifications of three non-executive directors approved, effective immediately [7] - Changshan Pharmaceutical has received a drug registration certificate for Heparin Sodium injection in Turkmenistan, used for anticoagulation [8] - Changshan Pharmaceutical's vice president has resigned for personal reasons but will continue to hold other positions within the company [9] Group 4 - Shaanxi Construction has won five major projects with a total bid amount exceeding 3.912 billion yuan, covering various sectors [10][11] - Huazhong Co., Ltd. reported a 1.6% month-on-month increase in pig sales revenue for November, with a total of 34.4 million yuan [12] - Yipin Hong's subsidiary has received a drug registration certificate for Levofloxacin oral solution, effective for treating various bacterial infections [13] Group 5 - Yabo Co., Ltd.'s subsidiary has won projects totaling 7.2933 million yuan, representing 2.13% of the company's audited revenue for 2024 [14] - Sunshine Nuohe plans to invest 20 million yuan in Biling Bio, acquiring a 2.0435% stake in the company focused on nanomedicine [15] - Jinzhi Technology has won projects totaling 76.172 million yuan, accounting for 4.3% of the company's projected revenue for 2024 [16]

Core Viewpoint - Prolo Pharmaceutical Co., Ltd. has received a food production license for bat moth mycelium powder, indicating its capability to produce related food products and additives, which will help meet market demand and expand its health food business [1] Group 1 - The company’s wholly-owned subsidiary, Zhejiang Prolo Biotechnology Co., Ltd., obtained the food production license from the Zhejiang Provincial Market Supervision Administration [1] - The acquisition of the food production license signifies the company's qualification for producing specific varieties, enhancing its operational capabilities in food and food additive production [1] - The company has established a sustainable health food production capacity through advanced synthetic biology technology, covering the entire process from process design to large-scale fermentation production [1]

证券代码：000739 证券简称：普洛药业 公告编号：2025-76 普洛药业股份有限公司 关于取得食品生产许可证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，普洛药业股份有限公司（以下简称"公司"）全资子公司浙江普洛生 物科技有限公司收到浙江省市场监督管理局颁发的蝙蝠蛾被毛孢菌丝体粉的《食 品生产许可证》。现将有关情况公告如下： 三、对公司的影响 公司本次取得《食品生产许可证》，标志着公司具备了相关品种的生产资质， 有助于开展相关食品以及食品添加剂生产经营活动，更好地满足市场需求；也标 志着公司依托先进的合成生物学技术平台，实现了从工艺路线设计、高效生物合 成到规模化发酵生产的全流程、可持续的保健食品生产能力，对公司未来拓展保 健食品领域业务具有积极意义。 四、风险提示 公司一直高度重视产品研发，并非常注重产品研发、制造及销售等环节的质 1、生产者名称：浙江普洛生物科技有限公司 2、法定代表人：金毅强 3、生产地址：浙江省金华市东阳市歌山镇 4、食品类别：保健食品 量、安全和合规。但是产品的生产和销售可能会受到政策法规、市场环境变化等 不确定 ...

Core Viewpoint - Prolo Pharmaceutical's subsidiary has received a food production license, enhancing its capabilities in the health food sector [1] Group 1 - Prolo Pharmaceutical's subsidiary, Zhejiang Prolo Biotechnology Co., Ltd., has been granted a food production license by the Zhejiang Provincial Market Supervision Administration [1] - The acquisition of the food production license signifies that the company is now qualified to produce relevant products, facilitating its operations in food and food additives [1] - This development highlights the company's ability to leverage advanced synthetic biology technology, achieving a sustainable production capacity for health food through a complete process from route design to large-scale fermentation [1]

人民财讯12月11日电，普洛药业（000739）12月11日公告，近日，公司全资子公司浙江普洛生物科技有 限公司收到浙江省市场监督管理局颁发的蝙蝠蛾被毛孢菌丝体粉的《食品生产许可证》，食品类别为保 健食品。 ...

Group 1: SAIC Motor Corporation - In November, SAIC Motor's total vehicle sales reached 460,800 units, a year-on-year decrease of 3.75% [1] - New energy vehicle sales were 209,400 units, showing a year-on-year increase of 19.75% [1] - Cumulative vehicle sales from January to November reached 4,108,100 units, a year-on-year increase of 16.38% [1] - SAIC's subsidiary plans to establish a private equity fund focused on the smart electric vehicle industry with an initial subscription size of 1.09 billion yuan [1] Group 2: Top Group - Top Group is planning to issue H-shares and list on the Hong Kong Stock Exchange [2] - The company is in discussions with relevant intermediaries regarding the specifics of the H-share listing [2] Group 3: Ningbo Fuda - Ningbo Fuda's subsidiary intends to publicly sell 100% equity of its subsidiary, Hekou Yingzhou Cement Company, with an assessed value of 1.5752 million yuan [4] Group 4: Fuguang Co., Ltd. - Fuguang Co., Ltd. plans to sell a 25% stake in its associate company, Xiaotunpai, for 67.2636 million yuan [5] Group 5: Puluo Pharmaceutical - Puluo Pharmaceutical's subsidiary received a drug registration certificate for Amoxicillin and Clavulanate Potassium Tablets, used for various infections [6][7] Group 6: Fosun Pharma - Fosun Pharma's subsidiary received approval to conduct Phase I clinical trials for a dual-specific antibody injection for treating advanced solid tumors [8] Group 7: Far East Group - Far East Group's subsidiaries won contracts totaling 2.383 billion yuan in November [9] Group 8: Samsung Medical - Samsung Medical's subsidiary is expected to win a procurement project from the State Grid worth approximately 124 million yuan [10] Group 9: Changhua Group - Changhua Group received a development notification from a domestic automaker, with an expected total sales amount of approximately 732 million yuan over five years [12] Group 10: Xinbang Intelligent - Xinbang Intelligent's application for issuing shares to acquire Wuxi Yindichip Microelectronics has been accepted by the Shenzhen Stock Exchange [14] Group 11: Jinjing Development - Jinjing Development's subsidiary won a residential and commercial land bid in Tianjin for 474 million yuan [16] Group 12: Guohong Holdings - Guohong Holdings signed an investment framework agreement to develop a strategic emerging industry park in Tanzhou Town [17] Group 13: Hanma Technology - Hanma Technology reported a 149.94% year-on-year increase in truck sales in November, totaling 2,002 units [22] Group 14: Yufeng Group - Yufeng Group decided to terminate its plan to issue A-shares due to the expiration of authorization and market conditions [24] Group 15: Zhenhua Electric - Zhenhua Electric's subsidiary plans to invest up to 201 million yuan in a private equity fund focused on specific industries, including new energy [28] Group 16: Fuao Co., Ltd. - Fuao Co., Ltd. completed the transfer of 40% equity in Fuao Wan'an for 26.222 million yuan [29] Group 17: Baotailong - Baotailong plans to acquire an additional 2.83% stake in its subsidiary, totaling 15 million yuan [31] Group 18: Zhongchao Holdings - Zhongchao Holdings' subsidiaries won projects totaling 1.318 billion yuan [32] Group 19: Annie Co., Ltd. - Annie Co., Ltd. announced a potential change in control, leading to a temporary suspension of its stock [34] Group 20: Ganfeng Lithium - Ganfeng Lithium's subsidiary plans to issue $100 million in exchangeable notes [38]

格隆汇12月1日丨普洛药业(000739.SZ)公布，全资子公司浙江普洛巨泰药业有限公司收到国家药品监督 管理局签发的阿莫西林克拉维酸钾片《药品注册证书》。本品用于治疗以下感染:上呼吸道感染(包括 耳、鼻、喉科)：复发性扁桃体炎、鼻窦炎、中耳炎。下呼吸道感染：急、慢性支气管炎(尤适用于严重 感染)、大叶性肺炎、支气管肺炎。泌尿系统感染：膀胱炎(特别是感染反复发作或复杂感染,不包括前列 腺炎)。皮肤和软组织感染：如蜂窝组织炎、动物咬伤合并伤口感染。口腔感染：严重的齿龈脓肿合并 颌面部蜂窝组织炎。 ...

2025年1至6月份，普洛药业的营业收入构成为：医药行业占比99.6%，其他业务占比0.4%。 截至发稿，普洛药业市值为187亿元。 每经AI快讯，普洛药业（SZ 000739，收盘价：16.18元）12月1日晚间发布公告称，近日，普洛药业股 份有限公司全资子公司浙江普洛巨泰药业有限公司收到国家药品监督管理局签发的阿莫西林克拉维酸钾 片《药品注册证书》。 每经头条（nbdtoutiao）——5年期大面积下线，3年期利率低至1.5%仍一单难求：要么"售罄"要么"额度 紧张"！中长期大额存单为何在消失？ （记者 曾健辉） ...

证券代码：000739 证券简称：普洛药业 公告编号：2025-75 普洛药业股份有限公司 关于获得药品注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，普洛药业股份有限公司（以下简称"公司"）全资子公司浙江普洛巨 泰药业有限公司收到国家药品监督管理局（以下简称"药监局"）签发的阿莫西 林克拉维酸钾片《药品注册证书》。现将有关情况公告如下： 一、药品注册批准情况 1、产品名称：阿莫西林克拉维酸钾片 2、剂型：片剂 3、规格：1.0g（C16H19N3O5S 0.875g 与 C8H9NO50.125g） 4、注册分类：化学药品 4 类 6、生产企业：浙江普洛巨泰药业有限公司 7、证书编号：2025S03441 8、药品批准文号：国药准字 H20255971 9、审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查， 本品符合药品注册的有关要求，批准注册，发给药品注册证书。 二、药品其他相关情况 本品用于治疗以下感染:上呼吸道感染(包括耳、鼻、喉科)：复发性扁桃体 炎、鼻窦炎、中耳炎。下呼吸道感染：急、慢性支气管炎(尤适用于严重感染) ...